A recent study reported in the Renal and Urology News show that continuous ADT treatment has a better survival rate than the present procedure of intermittent ADT treatment.
Hormonal treatment (ADT treatment) are presently prescribed in monthly or three monthly sessions for one to three years. The main rational being the body will development resistance to the hormones induced. There is also a re-challenge stage if the PSA starts to rise again.
The new17 years old study shows a better survival rate if ADT treatments are continuous until the point of resistance by the body. It is obviously not a case of one solution for all cases.
Extract from the report.